BEAM
Beam Therapeutics Inc.
$27.24
+0.46%
$2.8B
No data for this timeframe.
Vol
Market Cap$2.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$680.0M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 9S
Insider Net $-$3.7M
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001745999·Prev Close $27.11
Recent Activity
May 20, 2026
short_volume
Short Volume: BEAM — 75.9% short (0.7M / 0.9M)
Short: 683,508 | Exempt: 10 | TRF Vol: 900,813 | Short Ratio: 75.9% | Off-exchange volume (dark pool
May 12, 2026
Press
Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog
Impact 7/10
Apr 17, 2026
SEC
Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual meeting. The filing
DEFA14A — Impact 3/10
Apr 1, 2026
Insider
Evans John M. sold 30,078 shares
CEO @ $24.58 ($739.3K)
Apr 1, 2026
Insider
Simon Amy sold 6,700 shares
Chief Medical Officer @ $24.58 ($164.7K)
Apr 1, 2026
Insider
Bellon Christine sold 5,956 shares
Chief Legal Officer @ $24.58 ($146.4K)
Mar 5, 2026
SEC
Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale
8-K — Impact 4/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
1,120,389 shares ($31.1M)
Price Targets
$51.07
+87.5% upside
Strong Buy
Current $27.24
Low $26.00
Median $47.00
High $80.00
15 analysts
$26.00
$80.00
Analyst Ratings
11Strong Buy
11Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| Feb 25, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Feb 20, 2026 | Canaccord Genuity | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.15 ▼ -9.6% | $-1.24 — $-0.95 | -15% YoY | 12 |
| Next Q | $-1.20 ▼ -10.3% | $-1.28 — $-0.96 | -9% YoY | 12 |
| Current FY | $-4.51 ▼ -4.4% | $-4.76 — $-3.80 | -456% YoY | 14 |
| Next FY | $-4.82 ▼ -9.8% | $-5.90 — $-4.08 | -7% YoY | 12 |
Latest Reports
BULLISH
Press
7/10
Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog
May 12, 2026
NEUTRAL
DEFA14A
3/10
Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual meeting. The filing
Apr 17, 2026
NEUTRAL
8-K
4/10
Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $330.1M | ADD |
| VANGUARD GROUP INC | $254.8M | — |
| TWO SIGMA INVESTMENTS, LP | $31.1M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $23.1M | NEW |
| MORGAN STANLEY | $20.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Evans John | SELL | $739.3K |
| Apr 1, 2026 | Simon Amy | SELL | $164.7K |
| Apr 1, 2026 | Bellon Christine | SELL | $146.4K |
| Apr 1, 2026 | Cavanagh Bethany | SELL | $79.7K |
| Apr 1, 2026 | Ciaramella Giuseppe | SELL | $290.3K |
8 institutional holders with $680.0M total value (24,530,212 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, TWO. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 11,909,138 | $330.1M | 48.5% | ADD +63.7% |
| 2 | VANGUARD GROUP INC | 9,193,474 | $254.8M | 37.5% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,120,389 | $31.1M | 4.6% | DOUBLED +195.6% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 834,795 | $23.1M | 3.4% | NEW |
| 5 | MORGAN STANLEY | 729,400 | $20.2M | 3.0% | TRIM -50.7% |
| 6 | BANK OF AMERICA CORP /DE/ | 427,328 | $11.8M | 1.7% | TRIM -45.1% |
| 7 | WELLS FARGO & COMPANY/MN | 159,188 | $4.4M | 0.6% | ADD +35.7% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 156,500 | $4.3M | 0.6% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 379,044 | 1,120,389 | +195.6% | $31.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 779,024 | 427,328 | -45.1% | $11.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 117,323 | 159,188 | +35.7% | $4.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 156,500 | — | $4.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,307,156 | 644,760 | -50.7% | $15.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 561,521 | 379,044 | -32.5% | $9.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 83,411 | 117,323 | +40.7% | $2.8M | 2025-Q3 |
| FMR LLC | ADD | 7,920,053 | 12,961,459 | +63.7% | $220.5M | 2025-Q2 |
| MORGAN STANLEY | ADD | 822,961 | 1,307,156 | +58.8% | $22.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 673,780 | 851,336 | +26.4% | $14.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 369,201 | 561,521 | +52.1% | $9.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 136,873 | 83,411 | -39.1% | $1.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 12,107 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | DOUBLED | 3,317,294 | 7,920,053 | +138.8% | $154.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 117,088 | 369,201 | +215.3% | $7.2M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 22,907 | 12,107 | -47.1% | $236.4K | 2025-Q1 |
| NORGES BANK | EXIT | 18,591 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,648,195 | 2,183,246 | +32.5% | $54.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 189,194 | 1,819,636 | +861.8% | $45.1M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,207,757 | 795,319 | -34.1% | $19.7M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 22,907 | — | $568.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 803,829 | 1,207,757 | +50.3% | $29.6M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 629,492 | — | $15.4M | 2024-Q3 |
6 unique insiders with 9 transactions. Net insider value: -$3.7M ($0.00 bought, $3.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Evans John M. | CEO | SELL | 30,078 | $24.58 | $739.3K |
| Apr 1, 2026 | Simon Amy | Chief Medical Officer | SELL | 6,700 | $24.58 | $164.7K |
| Apr 1, 2026 | Bellon Christine | Chief Legal Officer | SELL | 5,956 | $24.58 | $146.4K |
| Apr 1, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | SELL | 3,242 | $24.58 | $79.7K |
| Apr 1, 2026 | Ciaramella Giuseppe | President | SELL | 11,810 | $24.58 | $290.3K |
| Mar 31, 2026 | Simon Amy | Chief Medical Officer | A | 31,750 | $0.00 | $0.00 |
| Mar 31, 2026 | Ciaramella Giuseppe | President | A | 40,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Emany Sravan Kumar | Chief Financial Officer | A | 31,750 | $0.00 | $0.00 |
| Mar 31, 2026 | Bellon Christine | Chief Legal Officer | A | 20,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Evans John M. | CEO | M | 25,000 | $0.6700 | $16.8K |
| Mar 31, 2026 | Evans John M. | CEO | SELL | 25,000 | $22.76 | $569.1K |
| Mar 31, 2026 | Evans John M. | CEO | A | 90,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Evans John M. | CEO | M | 25,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | A | 20,000 | $0.00 | $0.00 |
| Mar 30, 2026 | Evans John M. | CEO | M | 25,000 | $0.6700 | $16.8K |
| Mar 30, 2026 | Evans John M. | CEO | SELL | 25,000 | $22.37 | $559.2K |
| Mar 30, 2026 | Evans John M. | CEO | M | 25,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Ciaramella Giuseppe | President | M | 35,000 | $17.00 | $595.0K |
| Feb 24, 2026 | Ciaramella Giuseppe | President | M | 35,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | A | 40,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Bellon Christine | Chief Legal Officer | A | 40,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Evans John M. | CEO | A | 180,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Ciaramella Giuseppe | President | A | 80,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Emany Sravan Kumar | Chief Financial Officer | A | 63,500 | $0.00 | $0.00 |
| Jan 31, 2026 | Simon Amy | Chief Medical Officer | A | 88,500 | $0.00 | $0.00 |
| Jan 30, 2026 | Evans John M. | CEO | M | 25,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Evans John M. | CEO | SELL | 22,094 | $28.27 | $624.7K |
| Jan 30, 2026 | Evans John M. | CEO | M | 25,000 | $0.6700 | $16.8K |
| Jan 29, 2026 | Evans John M. | CEO | M | 19,336 | $0.00 | $0.00 |
| Jan 29, 2026 | Evans John M. | CEO | SELL | 16,333 | $29.19 | $476.8K |
| Jan 29, 2026 | Evans John M. | CEO | M | 19,336 | $0.6700 | $13.0K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
Current analyst consensus: Strong Buy (88% buy). Based on 25 analysts: 11 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$51.07 mean target
+87.5% upside
Strong Buy (1.29)
$26.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $27.24 |
| Target Low | $26.00 |
| Target Mean | $51.07 |
| Target Median | $47.00 |
| Target High | $80.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.15 | $-1.24 | $-0.95 | -14.5% | -9.6% | 2↑ 8↓ | $0.0B | 89.8% | 12 |
| Next Q 2026-09-30 |
$-1.20 | $-1.28 | $-0.96 | -8.7% | -10.3% | 2↑ 8↓ | $0.0B | 66.7% | 12 |
| Current FY 2026-12-31 |
$-4.51 | $-4.76 | $-3.80 | -456.3% | -4.4% | 7↑ 5↓ | $0.1B | -47.6% | 14 |
| Next FY 2027-12-31 |
$-4.82 | $-5.90 | $-4.08 | -6.9% | -9.8% | 5↑ 6↓ | $0.1B | 25.8% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.145 | |
| 7d ago | $-1.146 | +0.001 |
| 30d ago | $-1.045 | -0.100 |
| 60d ago | $-1.035 | -0.110 |
| 90d ago | $-1.183 | +0.038 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 25, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 20, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Jan 21, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 7, 2026 | UBS | INITIATE | — | Neutral |
| Nov 24, 2025 | Evercore ISI Group | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 11 | 10 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 10 | 10 | 3 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
short_volume
Short Volume: BEAM — 75.9% short (0.7M / 0.9M)
Short: 683,508 | Exempt: 10 | TRF Vol: 900,813 | Short Ratio: 75.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: BEAM — 65.5% short (0.4M / 0.6M)
Short: 387,674 | Exempt: 0 | TRF Vol: 591,745 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
fda
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and
May 18, 2026
short_volume
Short Volume: BEAM — 64.0% short (0.5M / 0.7M)
Short: 471,379 | Exempt: 200 | TRF Vol: 736,462 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: BEAM — 65.0% short (0.5M / 0.8M)
Short: 503,315 | Exempt: 730 | TRF Vol: 774,148 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: BEAM — 60.8% short (0.6M / 1.1M)
Short: 649,064 | Exempt: 60 | TRF Vol: 1,067,466 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
May 12, 2026
fda
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
<p>CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7lNR8R1PWPAqUSA882jXfxMYWJzLqO9IiJbsVE-Maf
May 12, 2026
earnings_calendar
BEAM Q1 2026 Earnings Scheduled — 2026-05-12
May 12, 2026
short_volume
Short Volume: BEAM — 55.5% short (0.3M / 0.5M)
Short: 284,683 | Exempt: 386 | TRF Vol: 513,389 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
<p align="center"><em>Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile
May 6, 2026
short_volume
Short Volume: BEAM — 64.0% short (0.5M / 0.7M)
Short: 469,342 | Exempt: 4,575 | TRF Vol: 733,595 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: BEAM — 56.9% short (0.4M / 0.7M)
Short: 389,873 | Exempt: 709 | TRF Vol: 685,771 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
BEAM Q1 2026 Earnings Scheduled — 2026-05-04
May 4, 2026
short_volume
Short Volume: BEAM — 65.1% short (0.4M / 0.6M)
Short: 420,315 | Exempt: 1 | TRF Vol: 645,234 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: BEAM — 67.5% short (0.4M / 0.5M)
Short: 363,989 | Exempt: 5,688 | TRF Vol: 539,369 | Short Ratio: 67.5% | Off-exchange volume (dark pool + OTC)